Impact of Chemoradiotherapy for First Primary Lung Cancer on the Prognosis and Re-chemoradiotherapy Sensitivity of Second Primary Lung Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2025 Feb 11

PMID 39931060

Authors

Zhe Chen

Gaoming Wang

Nan Wang

Jiangjiang Liu

Yu Yao

Haitao Ma

Jing Luo

Kai Xie

Affiliations

Soon will be listed here.

Abstract

Background: Despite undergoing surgery and chemoradiotherapy, patients with first primary lung cancer (FPLC) remain at risk for second primary lung cancer (SPLC), which is associated with a poor prognosis. The effects of FPLC chemoradiotherapy on SPLC prognosis and its sensitivity to re-chemoradiotherapy have not been adequately investigated.

Methods: This cohort study analyzed data from 23,827 patients who underwent FPLC surgery during 1973-2021, drawn from the Surveillance, Epidemiology, and End Results database. Among these, 5,302 FPLC patients developed SPLC within 5 years of their initial diagnosis. We employed the Fine-Gray competitive risk model, Cox proportional hazards model, and restricted mean survival time analysis to assess the effects of FPLC radiotherapy and chemotherapy on SPLC risk and survival differences.

Results: The competitive risk model indicated that FPLC radiotherapy and chemotherapy did not significantly change the risk of developing SPLC. However, the Cox proportional hazards model revealed that FPLC radiotherapy was associated with decreased overall survival (OS; HR=1.251, P<0.001) and cancer-specific survival (CSS; HR=1.228, P=0.001) in patients with SPLC. Conversely, FPLC chemotherapy was linked to improved OS (HR=0.881, P=0.012) in this population. Patients with SPLC who received combined chemoradiotherapy for FPLC exhibited significantly reduced survival times (OS: HR=1.157, P=0.030; CSS: HR=1.198, P=0.018), a finding confirmed across multiple models. For SPLC patients with prior FPLC chemoradiotherapy, subsequent SPLC radiotherapy significantly improved prognosis. Notably, this benefit is even more pronounced in patients who have not received prior chemoradiotherapy. While SPLC chemotherapy enhanced OS for patients who did not receive FPLC chemotherapy, it was associated with reduced CSS for those who had.

Conclusions: Overall, FPLC chemoradiotherapy influences SPLC prognosis and influences sensitivity to treatment. Tailoring SPLC management to FPLC treatment regimens may improve survival outcomes.

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

Hamaji M, Ali S, Burt B . A meta-analysis of resected metachronous second non-small cell lung cancer. Ann Thorac Surg. 2015; 99(4):1470-8. DOI: 10.1016/j.athoracsur.2014.11.033. View

Han S, Rivera G, Tammemagi M, Plevritis S, Gomez S, Cheng I . Risk Stratification for Second Primary Lung Cancer. J Clin Oncol. 2017; 35(25):2893-2899. PMC: 5946715. DOI: 10.1200/JCO.2017.72.4203. View

Hu F, Lito P . Insights into how adeno-squamous transition drives KRAS inhibitor resistance. Cancer Cell. 2024; 42(3):330-332. DOI: 10.1016/j.ccell.2024.02.014. View

Reinmuth N, Stumpf A, Stumpf P, Muley T, Kobinger S, Hoffmann H . Characteristics and outcome of patients with second primary lung cancer. Eur Respir J. 2012; 42(6):1668-76. DOI: 10.1183/09031936.00022512. View

Trab T, Baech J, Jakobsen L, Husby S, Severinsen M, Eloranta S . Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study. Lancet Haematol. 2023; 10(10):e838-e848. DOI: 10.1016/S2352-3026(23)00212-0. View

Sorin M, Prosty C, Ghaleb L, Nie K, Katergi K, Shahzad M . Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024; 10(5):621-633. PMC: 10958389. DOI: 10.1001/jamaoncol.2024.0057. View

Wang Z, Zhang J . Genetic and epigenetic bases of long-term adverse effects of childhood cancer therapy. Nat Rev Cancer. 2024; 25(2):129-144. DOI: 10.1038/s41568-024-00768-6. View

Jensen S, Moore D, Surani A, Crosbie P, Rosenfeld N, Rintoul R . Second Primary Lung Cancer - An Emerging Issue in Lung Cancer Survivors. J Thorac Oncol. 2024; 19(10):1415-1426. DOI: 10.1016/j.jtho.2024.07.014. View

10.

Preston D, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M . Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 2007; 168(1):1-64. DOI: 10.1667/RR0763.1. View

11.

Chen K, Liu C, Li X, Chen T, Liu S, Xiong F . Risk and prognosis of secondary lung cancer after radiation therapy for thoracic malignancies. Clin Respir J. 2024; 18(5):e13760. PMC: 11082536. DOI: 10.1111/crj.13760. View

12.

Safavi A, Mak D, Gabriel Boldt R, Chen H, Louie A . Stereotactic ablative radiotherapy in T1-2N0M0 small cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 2021; 160:179-186. DOI: 10.1016/j.lungcan.2021.07.007. View

13.

Guan X, Wei R, Yang R, Lu Z, Liu E, Zhao Z . Association of Radiotherapy for Rectal Cancer and Second Gynecological Malignant Neoplasms. JAMA Netw Open. 2021; 4(1):e2031661. PMC: 7794669. DOI: 10.1001/jamanetworkopen.2020.31661. View

14.

Zhou B, Zang R, Song P, Zhang M, Bie F, Bai G . Association between radiotherapy and risk of second primary malignancies in patients with resectable lung cancer: a population-based study. J Transl Med. 2023; 21(1):10. PMC: 9827664. DOI: 10.1186/s12967-022-03857-y. View

15.

Gonzalez S, Lopez-Bigas N, Gonzalez-Perez A . Copy number footprints of platinum-based anticancer therapies. PLoS Genet. 2023; 19(2):e1010634. PMC: 9956877. DOI: 10.1371/journal.pgen.1010634. View

16.

Tian H, Bai G, Yang Z, Chen P, Xu J, Liu T . Multiple primary lung cancer: Updates of clinical management and genomic features. Front Oncol. 2023; 13:1034752. PMC: 9993658. DOI: 10.3389/fonc.2023.1034752. View

17.

Popp I, Vaes R, Wieten L, Adebahr S, Hendriks L, Haghighi E . Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: A pooled analysis of two institutions prospective phase II single arm trials. Radiother Oncol. 2023; 190:110048. DOI: 10.1016/j.radonc.2023.110048. View

18.

Mathew G, Agha R, Albrecht J, Goel P, Mukherjee I, Pai P . STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int J Surg. 2021; 96:106165. DOI: 10.1016/j.ijsu.2021.106165. View

19.

Donin N, Kwan L, Lenis A, Drakaki A, Chamie K . Second primary lung cancer in United States Cancer Survivors, 1992-2008. Cancer Causes Control. 2019; 30(5):465-475. DOI: 10.1007/s10552-019-01161-7. View

20.

Wang Z, Wilson C, Easton J, Thrasher A, Mulder H, Liu Q . Genetic Risk for Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer. J Clin Oncol. 2018; 36(20):2078-2087. PMC: 6036620. DOI: 10.1200/JCO.2018.77.8589. View